



SURGERY-BASED MULTIMODALITY THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA

June 13- 14, 2008

AT THE

**Renaissance Dallas Hotel
Dallas, Texas**

SPONSORED BY

**International Mesothelioma Program
and the Division of Thoracic Surgery
Brigham and Women's Hospital**

UNDER THE DIRECTION OF

**David J. Sugarbaker, M.D.
Richard E. Wilson Professor of Surgical Oncology, Harvard Medical School
Chief, Thoracic Surgery, Brigham & Women's Hospital**

CO-DIRECTORS

**William Richards, Ph.D.
Assistant Professor of Surgery
Harvard Medical School
Brigham & Women's Hospital**

**Raphael Bueno, M.D.
Associate Professor of Surgery
Harvard Medical School
Associate Chief, Division
Brigham & Women's Hospital**

**Gavin Gordon, Ph.D.
Assistant Professor of Surgery
Harvard Medical School
Brigham & Women's Hospital**

**Harold C. Urschel, Jr., M.D.
Chair, Cardiovascular and
Thoracic Surgical Research,
Education, Clinical Excellence
Baylor University Medical Ctr.**

COURSE DESCRIPTION

This two-day symposium will provide an update to thoracic surgeons and allied specialists with regard to current diagnostic and staging criteria, and to the various surgery based multimodality management options that may be available to their patients. Surgeons, pathologists and other physicians who may have a limited experience with mesothelioma due to its low incidence will benefit from a concise presentation of the state of the art by the field's leaders. Those thoracic surgeons who may treat a small number of mesothelioma cases will benefit from insights provided by those from higher volume centers in the management of these difficult cases. The course topic is highly relevant as asbestos continues to exist ubiquitously in our society, and mesothelioma continues to present a challenge to those who treat diseases of the thorax. There will be Poster Session on the first evening. Abstracts should be submitted by May 1, 2008. Teaching will be done through interactive techniques, lectures and panels with the assistance of appropriate visual aides. A detailed syllabus will be provided. Included in the registration is a continental breakfast each morning, lunch with the faculty each day and a reception and dinner. A limited block of rooms has been reserved at the Renaissance Dallas Hotel Dallas. You are urged to make your reservations early.

OBJECTIVES

At the conclusion of this program, the participants will be able to:

- Identify the optimal diagnostic and staging studies for suspected mesothelioma.
- Evaluate high risk patients who would benefit from multimodality intervention.
- Identify candidates for clinical trials.

ACCREDITATION

Physicians: Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. Harvard Medical School designates this continuing medical education activity for xx credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association (AMA).

Physician Assistants: Application for continuing education credits has been made to the American Association of Physician Assistants.

SURGERY-BASED MULTIMODALITY THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA

Renaissance Dallas Hotel
Dallas, Texas

PRELIMINARY PROGRAM

FRIDAY – JUNE 13, 2008

7:15-7:50 Continental Breakfast

Introductory Remarks

7:50-8:00 Welcome Dr. W. Richards
8:00-8:30 Course Overview Dr. D. Sugarbaker

Session I – Etiology and Pathogenesis Moderators: Drs. J. Godleski/K. Kelsey

8:30-8:50 Asbestos Dr. J. Godleski
8:50-9:10 Epidemiology Dr. K. Kelsey
9:10-9:30 Causation Mr. R. Budd, Esq
9:30-10:00 Panel Discussion

10:00-10:15 Break

Session II – Diagnostic Advances Moderators: Drs. S. Hammar/L. Chirieac

10:15-10:35 Thoracoscopic Biopsy Dr. M. Crespo
10:35-10:55 Histologic variants Dr. S. Hammer
10:55-11:15 Immunohistochemistry Dr. L. Chirieac
11:15-11:35 Gene Ratio-Based Dx Dr. G. Gordon
11:35-12:00 Panel Discussion

12:00-1:30 Lunch

Session III – Staging Moderators: Drs. M. Jaklitsch/R. Flores

1:30-1:50 Role of PET Dr. R. Flores
1:50-2:10 Tumor Volume Dr. H. Pass
2:10-2:30 Pathologic Staging Dr. M. Jaklitsch
2:30-2:50 Prognostic Model Dr. W. Richards
2:50-3:15 Panel Discussion

3:15-3:30 Break

3:30-5:30 EPP and Cavitory Chemo Workshops
Drs. P. Sugarbaker/D. Sugarbaker

6:00-7:30 Cocktails/Poster Session/Video Session

8:00 Dinner Keynote speaker - TBD

SATURDAY – JUNE 14, 2008

7:15-8:00 Continental Breakfast

Session IV – Evolving Therapies Moderators: Drs. H. Kindler/R. Smythe

8:00-8:20 Conventional Chemotherapy Dr. H. Kindler
8:20-8:40 Targeted Chemotherapy Dr. R. Smythe
8:40-9:00 Neo-adjuvant Therapy Dr. W. Weder
9:00-9:30 Panel Discussion

9:30-10:00 Break

10:00-10:45 Case Presentations/Discussion
Drs. J. Wee/C. McNamee

Session V – Pros and Cons of Radiation Therapy Moderator: Dr. E. Baldini

10:45-11:05 RT Post-EPP Strategies Dr. E. Baldini
11:05-11:25 High Dose RT Dr. K. Rosenzweig
11:30-12:00 Panel Discussion

12:00-1:00 Lunch

Session VI – Novel Therapies Moderators: Robinson/Pass

1:00-1:20 Heated Chemotherapy Dr. L. Zellos
1:20-1:40 Resection if the Unresected
New Technologies in EPP Dr. D. Sugarbaker
1:40-2:00 Photodynamic Therapy Dr. J. Friedberg
2:00-2:20 Panel Discussion

2:20-2:40 Break

Session VII – Future Directions Moderators: Drs. R. Bueno/W. Weder

2:40-2:55 Genetic Sequencing Dr. R. Bueno
2:55-3:10 Integrative Medicine Dr. S. Gullans
3:10-3:25 Novel Targets Dr. D. Sugarbaker
3:25-3:40 Panel Discussion

3:40 Closing Remarks Dr. D. Sugarbaker

**Inquiries should be directed Harvard Medical School Continuing Education
Department by phone: (617) 384-8600, Monday-Friday, 10 a.m. to 4 p.m. (EST),
or by e-mail: hms-cme@hms.harvard.edu.**